TIMP-1 and VEGF-165 Serum Concentration During First-line Therapy of Ovarian Cancer Patients

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2010 Apr 15

PMID 20388222

Citations 23

Authors

Sven Mahner

Linn Woelber

Christine Eulenburg

Joerg Schwarz

Walter Carney

Fritz Jaenicke

Karin Milde-Langosch

Volkmar Mueller

Affiliations

Soon will be listed here.

Abstract

Background: Angiogenesis appears to play an important role in ovarian cancer. Vascular endothelial growth factor (VEGF) has recently been implicated as a therapeutic target in ovarian cancer. The tissue inhibitor of metalloproteinase 1 (TIMP-1) is involved in tissue invasion and angiogenesis. The application of serum TIMP-1 and VEGF to monitor primary therapy and predict clinical outcome of patients with ovarian cancer is unclear.

Methods: Patients with epithelial ovarian cancer who presented for primary surgery were included in this study. A total of 148 serum samples from 37 patients were analyzed. Samples were prospectively collected at 4 predefined time points: 1. before radical debulking surgery, 2. after surgery and before platinum/taxane based chemotherapy, 3. during chemotherapy, 4. after chemotherapy. Serum VEGF-165 and TIMP-1 as well as CA-125 were quantified by ELISA or ECLIA and correlation with response and long-term clinical outcome was analyzed.

Results: Serum levels of all markers changed substantially during first-line therapy. High CA-125 (p = 0.002), TIMP-1 (p = 0.007) and VEGF-165 (p = 0.02) after chemotherapy were associated with reduced overall survival. In addition, elevated CA-125 (p < 0.001) and VEGF-165 (p = 0.006) at this time point predicted poor progression-free survival. TIMP-1 and VEGF-165 were closely correlated at all time-points during therapy.

Conclusions: TIMP-1 and VEGF serum levels changed significantly during first-line therapy of ovarian cancer patients and predicted prognosis. These findings support the role of angiogenesis in ovarian cancer progression and the use of antiangiogenic therapy.

Citing Articles

The Vascular Endothelial Growth Factor-A121/Vascular Endothelial Growth Factor-A165 Ratio as a Predictor of the Therapeutic Response to Immune Checkpoint Inhibitors in Gastric Cancer.

Hamada Y, Tanoue K, Arigami T, Yamakuchi M, Okawa M, Matsushita D Cancers (Basel). 2024; 16(23).

PMID: 39682145 PMC: 11640175. DOI: 10.3390/cancers16233958.

Role of Cancer Side Population Stem Cells in Ovarian Cancer Angiogenesis.

Pan Y, Yang X, Chen M, Shi K, Lyu Y, Meeson A Med Princ Pract. 2024; 33(5):403-413.

PMID: 39068919 PMC: 11460956. DOI: 10.1159/000539642.

Yang C, Zhu L, Lin Q Sci Rep. 2024; 14(1):1564.

PMID: 38238592 PMC: 10796408. DOI: 10.1038/s41598-024-52117-0.

Prognostic Role of Vascular Endothelial Growth Factor and Correlation with Oxidative Stress Markers in Locally Advanced and Metastatic Ovarian Cancer Patients.

Trifanescu O, Gales L, Tanase B, Marinescu S, Trifanescu R, Gruia I Diagnostics (Basel). 2023; 13(1).

PMID: 36611458 PMC: 9818969. DOI: 10.3390/diagnostics13010166.

Suppressing MDSC Infiltration in Tumor Microenvironment Serves as an Option for Treating Ovarian Cancer Metastasis.

Li Y, Zhang Q, Wu M, Zhang P, Huang L, Ai X Int J Biol Sci. 2022; 18(9):3697-3713.

PMID: 35813475 PMC: 9254473. DOI: 10.7150/ijbs.70013.

References

Rauvala M, Puistola U, Turpeenniemi-Hujanen T . Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol. 2005; 99(3):656-63. DOI: 10.1016/j.ygyno.2005.07.009. View

Huang L, Garrett A, Bell D, Welch W, Berkowitz R, Mok S . Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol. 2000; 77(3):369-76. DOI: 10.1006/gyno.2000.5806. View

Hicklin D, Ellis L . Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2004; 23(5):1011-27. DOI: 10.1200/JCO.2005.06.081. View

Gadducci A, Ferdeghini M, Fanucchi A, Annicchiarico C, Ciampi B, Prontera C . Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res. 1999; 19(2B):1401-5. View

Sakata K, Shigemasa K, Nagai N, Ohama K . Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol. 2000; 17(4):673-81. View

du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J . Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe.... Cancer. 2009; 115(6):1234-44. DOI: 10.1002/cncr.24149. View

Cannistra S . Cancer of the ovary. N Engl J Med. 2004; 351(24):2519-29. DOI: 10.1056/NEJMra041842. View

Gadducci A, Cosio S, Tana R, Genazzani A . Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol. 2008; 69(1):12-27. DOI: 10.1016/j.critrevonc.2008.05.001. View

Bast Jr R, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J . New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005; 15 Suppl 3:274-81. DOI: 10.1111/j.1525-1438.2005.00441.x. View

10.

Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P . Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999; 85(1):178-87. View

11.

Spannuth W, Sood A, Coleman R . Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol. 2008; 5(4):194-204. DOI: 10.1038/ncponc1051. View

12.

Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K . Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer. 1997; 76(9):1221-7. PMC: 2228134. DOI: 10.1038/bjc.1997.537. View

13.

Bookman M, Brady M, McGuire W, Harper P, Alberts D, Friedlander M . Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009; 27(9):1419-25. PMC: 2668552. DOI: 10.1200/JCO.2008.19.1684. View

14.

Rudlowski C, Pickart A, Fuhljahn C, Friepoertner T, Schlehe B, Biesterfeld S . Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer. 2006; 16 Suppl 1:183-9. DOI: 10.1111/j.1525-1438.2006.00307.x. View

15.

Makar A, Kristensen G, Kaern J, Bormer O, Abeler V, Trope C . Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol. 1992; 79(6):1002-10. View

16.

Garcia A, Hirte H, Fleming G, Yang D, Tsao-Wei D, Roman L . Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008; 26(1):76-82. DOI: 10.1200/JCO.2007.12.1939. View

17.

Yap T, Carden C, Kaye S . Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009; 9(3):167-81. DOI: 10.1038/nrc2583. View

18.

Mahner S, Baasch C, Schwarz J, Hein S, Wolber L, Janicke F . C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer. 2008; 99(8):1269-75. PMC: 2570515. DOI: 10.1038/sj.bjc.6604650. View

19.

Prat A, Parera M, Peralta S, Perez-Benavente M, Garcia A, Gil-Moreno A . Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol. 2007; 19(2):327-31. DOI: 10.1093/annonc/mdm495. View

20.

Dehaven K, Taylor D, Gercel-Taylor C . Comparison of serum vascular endothelial growth levels between patients with and without ovarian malignancies. Int J Gynecol Cancer. 2002; 12(6):715-9. DOI: 10.1046/j.1525-1438.2002.t01-1-01143.x. View